MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

10.38 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 3 4 Next >

MeiraGTx Holdings's Return On Capital Employed Overview ↗

March 15, 2023

Via Benzinga

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

March 14, 2023

From MeiraGTx

Via GlobeNewswire

MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms ↗

December 13, 2022

Via Benzinga

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

December 13, 2022

From MeiraGTx

Via GlobeNewswire

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

December 08, 2022

From MeiraGTx

Via GlobeNewswire

MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial ↗

June 28, 2022

Via Benzinga

MeiraGTx Hldgs: Q1 Earnings Insights ↗

May 12, 2022

MeiraGTx Hldgs (NASDAQ:MGTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

MeiraGTx to Participate in Upcoming Investor Conferences

November 22, 2022

From MeiraGTx

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

November 10, 2022

During Thursday's session, 97 companies made new 52-week lows.

Via Benzinga

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.

November 10, 2022

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

October 04, 2022

Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy

From MeiraGTx

Via GlobeNewswire

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

October 01, 2022

Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which...

From MeiraGTx

Via GlobeNewswire

Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness ↗

September 29, 2022

Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year.

Via Benzinga

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗

August 04, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

54 Biggest Movers From Yesterday ↗

December 08, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...

Via Benzinga

MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom ↗

December 07, 2021

MeiraGTx Holdings plc (NASDAQ: MGTX) has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (...

Via Benzinga

The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré ↗

December 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 01, 2021

Gainers Biophytis (NASDAQ:BPTS) shares mo...

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 18, 2021

Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 18, 2021

Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion....

Via Benzinga

Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More ↗

October 16, 2021

This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit...

Via Benzinga

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal ↗

September 14, 2021

Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.

Via Talk Markets

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.